Literature DB >> 11257049

In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.

D Szabó1, A Máthé, Z Filetóth, P Anderlik, L Rókusz, F Rozgonyi.   

Abstract

The in vitro and in vivo effectiveness of amikacin, cefepime, and imipenem was studied using a high inoculum of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. An in vitro susceptibility test at the standard inoculum predicted the in vivo outcome of amikacin or imipenem while it did not do so for cefepime due to the inoculum effect.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11257049      PMCID： PMC90458          DOI： 10.1128/AAC.45.4.1287-1291.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  Performance of a fluorescence polarization immunoassay system evaluated by therapeutic monitoring of four drugs.

Authors:  M Zaninotto; S Secchiero; C D Paleari; A Burlina
Journal:  Ther Drug Monit       Date:  1992-08       Impact factor: 3.681

2.  Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase.

Authors:  F Caron; L Gutmann; A Bure; B Pangon; J M Vallois; A Pechinot; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

4.  Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient.

Authors:  F J Botha; P van der Bijl; H I Seifart; D P Parkin
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

5.  Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.

Authors:  G L Drusano; K I Plaisance; A Forrest; C Bustamante; A Devlin; H C Standiford; J C Wade
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

6.  Pharmacokinetics of antibiotics in critically ill patients.

Authors:  R van Dalen; T B Vree
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 7.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

Review 8.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

Review 9.  Clinical strategies for serious infection: a North American perspective.

Authors:  J P Quinn
Journal:  Diagn Microbiol Infect Dis       Date:  1998-06       Impact factor: 2.803

10.  In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.

Authors:  B D Jett; D J Ritchie; R Reichley; T C Bailey; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191
View more
  5 in total

1.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

Review 2.  The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

Authors:  Pranita D Tamma; Jesus Rodriguez-Bano
Journal:  Clin Infect Dis       Date:  2017-04-01       Impact factor: 9.079

3.  Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan.

Authors:  Wen Liang Yu; Michael A Pfaller; Patricia L Winokur; Ronald N Jones
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

4.  Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology.

Authors:  Anne Marie Queenan; Barbara Foleno; Colleen Gownley; Ellyn Wira; Karen Bush
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

5.  Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia.

Authors:  Ruibin Wang; Sara E Cosgrove; Sarah Tschudin-Sutter; Jennifer H Han; Alison E Turnbull; Alice J Hsu; Edina Avdic; Karen C Carroll; Pranita D Tamma
Journal:  Open Forum Infect Dis       Date:  2016-06-20       Impact factor: 3.835
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.